Evaluation of the Dose-Response Relationship of Amlodipine and Losartan Combination in Patients with Essential Hypertension An 8-Week, Randomized, Double-Blind, Factorial, Phase II, Multicenter Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Chang-Gyu | - |
dc.contributor.author | Youn, Ho-Joong | - |
dc.contributor.author | Chae, Shung-Chull | - |
dc.contributor.author | Yang, Joo-Young | - |
dc.contributor.author | Kim, Moo-Hyun | - |
dc.contributor.author | Hong, Taek-Jong | - |
dc.contributor.author | Kim, Cheol Ho | - |
dc.contributor.author | Kim, Jae Joong | - |
dc.contributor.author | Hong, Bum-Kee | - |
dc.contributor.author | Jeong, Jin-Won | - |
dc.contributor.author | Park, Si-Hoon | - |
dc.contributor.author | Kwan, Jun | - |
dc.contributor.author | Choi, Young-Jin | - |
dc.contributor.author | Cho, Seung-Yun | - |
dc.date.accessioned | 2021-09-06T23:57:58Z | - |
dc.date.available | 2021-09-06T23:57:58Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1175-3277 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/109336 | - |
dc.description.abstract | Background: Despite recommendations for more intensive treatment and the availability of several effective treatments, hypertension remains uncontrolled in many patients. Objective: The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension. Methods: This was an 8-week, randomized, double-blind, factorial design, phase II, multicenter study conducted in outpatient hospital clinics among adult patients aged 18-75 years with essential hypertension. At screening, patients received placebo for 2-4 weeks. Eligible patients (n = 320) were randomized to one of eight treatment groups: amlodipine 5 mg or 10 mg, losartan 50 mg or 100 mg, amlodipine camsylate/losartan 5 mg/50 mg, 5 mg/100 mg, 10 mg/50 mg, or 10 mg/100 mg. Main Outcome Measures: The assumption of strict superiority was estimated using the mean change in sitting diastolic blood pressure (DBP) at 8 weeks. Safety was monitored through physical examinations, vital signs, laboratory test results, ECG, and adverse events. Results: The reduction in DBP at 8 weeks was significantly greater in patients treated with the combination therapies compared with the respective monotherapies for all specified comparisons except amlodipine camsylate/losartan 10 mg/100 mg versus amlodipine 10 mg. The incidence of adverse events in the group of patients treated with the amlodipine camsylate/losartan 10 mg/50 mg combination tended to be higher than for any other group (27.9%, 12/43); however, the effect was not statistically significant. Conclusion: Combination amlodipine camsylate/losartan (5 mg/50 mg, 5 mg/100 mg and 10 mg/50 mg) resulted in significantly greater BP lowering compared with amlodipine or losartan monotherapy, and was determined to be generally safe and tolerable in patients with essential hypertension. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ADIS INT LTD | - |
dc.subject | ISOLATED SYSTOLIC HYPERTENSION | - |
dc.subject | END-POINT REDUCTION | - |
dc.subject | HIGH BLOOD-PRESSURE | - |
dc.subject | CARDIOVASCULAR MORBIDITY | - |
dc.subject | DIABETIC-NEPHROPATHY | - |
dc.subject | EFFICACY | - |
dc.subject | TOLERABILITY | - |
dc.subject | MONOTHERAPY | - |
dc.subject | SAFETY | - |
dc.subject | LIFE | - |
dc.title | Evaluation of the Dose-Response Relationship of Amlodipine and Losartan Combination in Patients with Essential Hypertension An 8-Week, Randomized, Double-Blind, Factorial, Phase II, Multicenter Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Chang-Gyu | - |
dc.identifier.doi | 10.2165/11597170-000000000-00000 | - |
dc.identifier.scopusid | 2-s2.0-84863023379 | - |
dc.identifier.wosid | 000301278100004 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, v.12, no.1, pp.35 - 47 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | - |
dc.citation.title | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 35 | - |
dc.citation.endPage | 47 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ISOLATED SYSTOLIC HYPERTENSION | - |
dc.subject.keywordPlus | END-POINT REDUCTION | - |
dc.subject.keywordPlus | HIGH BLOOD-PRESSURE | - |
dc.subject.keywordPlus | CARDIOVASCULAR MORBIDITY | - |
dc.subject.keywordPlus | DIABETIC-NEPHROPATHY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | LIFE | - |
dc.subject.keywordAuthor | amlodipine | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordAuthor | losartan. | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.